Warning: getimagesize(): https:// wrapper is disabled in the server configuration by allow_url_fopen=0 in /home/averroeseg/public_html/wp-content/themes/Averroes/single-our_products.php on line 29

Warning: getimagesize(https://www.averroes-eg.com/wp-content/themes/Averroes/upload/Bg-Title.jpg): Failed to open stream: no suitable wrapper could be found in /home/averroeseg/public_html/wp-content/themes/Averroes/single-our_products.php on line 29

Averozolid (Tablets)

Anti-infective
Product

Averozolid

Active

Linezolid 600 mg Film coated tablet

Category
Anti-infective
Indication

Averozolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Averozolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.

Pneumonia

Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumonia .

Community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only).

Skin and Skin Structure Infections Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. linezolid has not been studied in the treatment of decubitus ulcers .Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

Vancomycin-resistant Enterococcus faecium Infections Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia.

Dose
Infection * Dosage and Route of Administration Recommended Duration of Treatment (consecutive days
Pediatric Patients† (Birth through 11 Years of Age) Adults and Adolescents (12 Years and Older)
Nosocomial pneumonia 10 mg/kg oral ‡ every 8 hours 600 mg oral every ‡ 12 hours 10 to 14
Community-acquired pneumonia, including concurrent bacteremia
Complicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia 10 mg/kg oral‡ every 8 hours 600 mg oral‡ every 12 hours 14 to 28
Uncomplicated skin and skin structure infections less than 5 yrs: 10 mg/kg oral ‡ every 8 hours 5-11 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral ‡ every 12 hours Adolescents: 600 mg oral ‡ every 12 hours 10 to 14